PRINT OUT

Product Pipeline

May 13. 2020

<Domestic>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
Preparation for launching
Phase III
NS-065/NCNP-01
(viltolarsen)
intractable disease・orphan disease Duchenne muscular dystrophy Co - development:
National Center of Neurology and Psychiatry
Nippon Shinyaku
Phase III NS-304
(selexipag)
intractable disease・orphan disease chronic thromboembolic pulmonary
hypertension
Nippon Shinyaku Co - developed with
Actelion Pharmaceuticals Japan Ltd.
Phase III NS-32
(ferric derisomaltose)
gynecology iron deficiency anemia Licensed - in from
Pharmacosmos A/S
Nippon Shinyaku
Phase III ZX008 intractable disease・orphan disease Dravet syndrome
Lennox-Gastaut syndrome
Licensed - in from
Zogenix, Inc.
Zogenix, Inc.
Phase II NS-304
(selexipag)
cardiovascular arteriosclerosis obliterans Nippon Shinyaku Nippon Shinyaku
Phase II NS-304
(selexipag)
orthopedics lumbar spinal stenosis Nippon Shinyaku Nippon Shinyaku
Phase II NS-580 gynecology endometriosis Nippon Shinyaku Nippon Shinyaku
Phase II NS-17
(azacitidine)
hematologic malignancies acute myeloid leukemia Licensed - in from
Celgene Corporation
Nippon Shinyaku
Phase I/II NS-87 hematologic malignancies secondary acute myeloid leukemia Licensed - in from
Jazz Pharmaceuticals plc
Nippon Shinyaku
Preparation for development NS-917 hematologic malignancies relapsed/refractory acute myeloid leukemia Licensed - in from
Delta-Fly Pharma, Inc.
Nippon Shinyaku

<Overseas>

Stage Code No.
(Generic name)
Therapeutic field Indications Origin Development
China
NDA filing
NM441
(prulifloxacin)
anti-infection bacterial infections Nippon Shinyaku Licensed - out to
Lee's Pharmaceutical Holdings Limited
US NDA filing
Phase III
NS-065/NCNP-01
(viltolarsen)
intractable disease・orphan disease Duchenne muscular dystrophy Co - development:
National Center of Neurology and Psychiatry
Nippon Shinyaku
Phase III NS-304
(selexipag)
intractable disease・orphan disease chronic thromboembolic pulmonary
hypertension
Nippon Shinyaku Licensed - out to
Johnson & Johnson
Phase I/II NS-018
(ilginatinib)
hematologic malignancies myelofibrosis Nippon Shinyaku Nippon Shinyaku
page-top